JAC Advance Access originally published online on March 17, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2004) 53, 797-803
© 2004 The British Society for Antimicrobial Chemotherapy
Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria
1 Department of Infection, GKT School of Medicine, St Thomas’ Hospital Campus, London, UK; 2 Theravance, Inc., 901 Gateway Blvd, South San Francisco, CA 94080, USA
Received 5 November 2003, returned 28 December 2003, revised 15 January 2004; accepted 2 February 2004
Objective: We compared the in vitro activity of telavancin with that of vancomycin, teicoplanin, linezolid, quinupristin/dalfopristin, moxifloxacin and ampicillin, penicillin or oxacillin as appropriate, by the NCCLS/EUCAST and BSAC methods.
Methods: The organisms (n = 401) included in the study were patient isolates from St Thomas’ Hospital and were selected to include representatives of the clinically important Gram-positive aerobic species. Susceptibility testing was performed by agar dilution methods on Mueller–Hinton agar according to the NCCLS/EUCAST guidelines, in comparison with Iso-Sensitest agar according to the BSAC guidelines.
Results: Telavancin was active against all the Gram-positive species tested and nearly 90% of isolates included in the study had telavancin MICs 
1 mg/L. Vancomycin-resistant enterococci and lactobacilli isolates with vancomycin MICs > 64 mg/L had telavancin MIC ranges of 0.5–8 and 2–16 mg/L, respectively. There was no evidence of cross-resistance with other comparator drugs. The results for telavancin for the two susceptibility testing methods were mostly either the same or within one doubling dilution.
Conclusion: The susceptibility breakpoints for telavancin have yet to be established, but it would appear that telavancin has superior potency to the other tested glycopeptides, and on a weight-for-weight basis displays activity that is comparable to, or better than, that of the other agents tested.
Keywords: Staphylococcus aureus, enterococci, streptococci, glycopeptides, susceptibility testing
* Corresponding author. Tel: +44-020-792-89292; Fax: +44-020-792-80730; E-mail: anna.king{at}kcl.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Kosowska-Shick, C. Clark, G. A. Pankuch, P. McGhee, B. Dewasse, L. Beachel, and P. C. Appelbaum Activity of Telavancin against Staphylococci and Enterococci Determined by MIC and Resistance Selection Studies Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4217 - 4224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. N. Leonard, C. Vidaillac, and M. J. Rybak Activity of Telavancin against Staphylococcus aureus Strains with Various Vancomycin Susceptibilities in an In Vitro Pharmacokinetic/Pharmacodynamic Model with Simulated Endocardial Vegetations Antimicrob. Agents Chemother., July 1, 2009; 53(7): 2928 - 2933. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. O. Darouiche, M. D. Mansouri, and M. J. Schneidkraut Comparative Efficacies of Telavancin and Vancomycin in Preventing Device-Associated Colonization and Infection by Staphylococcus aureus in Rabbits Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2626 - 2628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Charneski, P. N Patel, and D. Sym Telavancin: A Novel Lipoglycopeptide Antibiotic Ann. Pharmacother., May 1, 2009; 43(5): 928 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Yu. Lubenko, E. V. Strukova, M. V. Smirnova, S. N. Vostrov, Y. A. Portnoy, S. H. Zinner, and A. A. Firsov Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model J. Antimicrob. Chemother., November 1, 2008; 62(5): 1065 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. J. Brown, R. Hope, D. M. Livermore, G. Brick, K. Broughton, R. C. George, R. Reynolds, and on behalf of the BSAC Working Parties on Resistanc Non-susceptibility trends among enterococci and non-pneumococcal streptococci from bacteraemias in the UK and Ireland, 2001-06 J. Antimicrob. Chemother., November 1, 2008; 62(suppl_2): ii75 - ii85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Wong, S. L. Barriere, M. M. Kitt, and M. R. Goldberg Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects J. Antimicrob. Chemother., October 1, 2008; 62(4): 780 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Draghi, B. M. Benton, K. M. Krause, C. Thornsberry, C. Pillar, and D. F. Sahm In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative J. Antimicrob. Chemother., July 1, 2008; 62(1): 116 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Krause, M. Renelli, S. Difuntorum, T. X. Wu, D. V. Debabov, and B. M. Benton In Vitro Activity of Telavancin against Resistant Gram-Positive Bacteria Antimicrob. Agents Chemother., July 1, 2008; 52(7): 2647 - 2652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Draghi, B. M. Benton, K. M. Krause, C. Thornsberry, C. Pillar, and D. F. Sahm Comparative Surveillance Study of Telavancin Activity against Recently Collected Gram-Positive Clinical Isolates from across the United States Antimicrob. Agents Chemother., July 1, 2008; 52(7): 2383 - 2388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Attwood and K. L. LaPlante Telavancin: A novel lipoglycopeptide antimicrobial agent Am. J. Health Syst. Pharm., November 15, 2007; 64(22): 2335 - 2348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. T. M. Jansen, A. Verel, J. Verhoef, and D. Milatovic In Vitro Activity of Telavancin against Gram-Positive Clinical Isolates Recently Obtained in Europe Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3420 - 3424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Miro, C. Garcia-de-la-Maria, Y. Armero, E. de-Lazzari, D. Soy, A. Moreno, A. del Rio, M. Almela, C. A. Mestres, J. M. Gatell, et al. Efficacy of Telavancin in the Treatment of Experimental Endocarditis Due to Glycopeptide-Intermediate Staphylococcus aureus Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2373 - 2377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Barcia-Macay, S. Lemaire, M.-P. Mingeot-Leclercq, P. M. Tulkens, and F. Van Bambeke Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus J. Antimicrob. Chemother., December 1, 2006; 58(6): 1177 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Stryjewski, V. H. Chu, W. D. O'Riordan, B. L. Warren, L. M. Dunbar, D. M. Young, M. Vallee, V. G. Fowler Jr., J. Morganroth, S. L. Barriere, et al. Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 Study Antimicrob. Agents Chemother., March 1, 2006; 50(3): 862 - 867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Stucki, P. Gerber, F. Acosta, M. Cottagnoud, and P. Cottagnoud Efficacy of Telavancin against Penicillin-Resistant Pneumococci and Staphylococcus aureus in a Rabbit Meningitis Model and Determination of Kinetic Parameters Antimicrob. Agents Chemother., February 1, 2006; 50(2): 770 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. K. Sun, K. Duchin, C. H. Nightingale, J.-P. Shaw, J. Seroogy, and D. P. Nicolau Tissue Penetration of Telavancin after Intravenous Administration in Healthy Subjects Antimicrob. Agents Chemother., February 1, 2006; 50(2): 788 - 790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Reyes, R. Skinner, K. Kaniga, K. M. Krause, J. Shelton, G. P. Obedencio, A. Gough, M. Conner, and S. S. Hegde Efficacy of Telavancin (TD-6424), a Rapidly Bactericidal Lipoglycopeptide with Multiple Mechanisms of Action, in a Murine Model of Pneumonia Induced by Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4344 - 4346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Madrigal, L. Basuino, and H. F. Chambers Efficacy of Telavancin in a Rabbit Model of Aortic Valve Endocarditis Due to Methicillin-Resistant Staphylococcus aureus or Vancomycin-Intermediate Staphylococcus aureus Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3163 - 3165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Higgins, R. Chang, D. V. Debabov, J. Leung, T. Wu, K. M. Krause, E. Sandvik, J. M. Hubbard, K. Kaniga, D. E. Schmidt Jr., et al. Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., March 1, 2005; 49(3): 1127 - 1134. [Abstract] [Full Text] [PDF]
|
|